{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:09:50Z","timestamp":1786975790544,"version":"build-2736575974"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Androgen deprivation therapy (ADT) for prostate cancer (PC) has been linked to adverse events, such as cardiac events and osteoporosis. Whether these associations differ by race is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the association between ADT and time to cardiovascular and bone-related adverse events across racial groups.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, nationwide, population-based, cohort study used electronic health records from the Veterans Affairs Health Care System (VAHCS) database from January 2001 to December 2021, with follow-up until death or study end. Participants included veterans with PC. Patients undergoing bilateral orchiectomy, receiving gonadotropin-releasing hormone antagonists, or lacking data on race and ethnicity were excluded. Data analysis was performed from January to March 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Luteinizing hormone\u2013releasing hormone agonists (leuprolide, goserelin, or triptorelin) use as a time-dependent variable and first-line systemic therapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was time to first cardiovascular event (myocardial infarction, stroke, coronary heart disease, congestive heart failure, or peripheral vascular disease). Secondary outcomes included osteoporosis, bone fracture, and a composite event (any of these). Cox models assessed the association between ADT as a time-dependent covariate and time-to-event across all patients by race.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 790\u202f916 veterans with PC (30\u202f139 [4%] Hispanic; 145\u202f267 non-Hispanic Black [18%]; 598\u202f574 non-Hispanic White [76%]; and , 16\u202f936 other races [2%]), ADT was associated with increased risk of cardiovascular events (hazard ratio [HR], 1.16; 95% CI, 1.15-1.17;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), bone fractures (HR, 1.59; 95% CI, 1.55-1.62;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), osteoporosis (HR, 2.73; 95% CI, 2.65-2.80;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and composite event (HR, 1.29; 95% CI, 1.27-1.30;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). When stratified by race, ADT remained significantly associated with all outcomes among all races. Among Black patients, compared with White patients, the excess risk due to ADT was slightly lower for cardiovascular events (HR, 1.09 [95% CI, 1.06-1.17] vs 1.18 [95% CI, 1.16-1.19]) and bone fracture (HR, 1.35 [95% CI, 1.28-1.42] vs 1.65 [95% CI, 1.61-1.70]) but higher for osteoporosis (HR, 3.16 [95% CI, 2.95-3.38] vs 2.64 [95% CI, 2.56-2.73]). HRs for Hispanic patients and those of other races were very similar to those for White patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of 790\u202f916 veterans with PC, ADT was associated with increased cardiovascular and bone risks across all racial groups. Although excess risks differed slightly between Black and White patients, overall differences were small. These findings highlight the need for monitoring and mitigation strategies for patients receiving ADT.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.45705","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:00:23Z","timestamp":1763568023000},"page":"e2545705","source":"Crossref","is-referenced-by-count":2,"title":["Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Nadine A.","family":"Friedrich","sequence":"first","affiliation":[{"name":"Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Janes","sequence":"additional","affiliation":[{"name":"Department of Surgery, Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Parrish","sequence":"additional","affiliation":[{"name":"Department of Surgery, Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"De Hoedt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiranbir","family":"Josan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Tatonetti","sequence":"additional","affiliation":[{"name":"Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[{"name":"Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Department of Surgery, Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"5","key":"zoi251238r2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them.","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"zoi251238r3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer.","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"zoi251238r4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi251238r5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients.","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"zoi251238r6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaccao.2024.04.004","article-title":"Social determinants of health mediate racial disparities in cardiovascular disease in men with prostate cancer.","volume":"6","author":"Demissei","year":"2024","journal-title":"JACC CardioOncol"},{"key":"zoi251238r7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics.","volume":"531","author":"Lowder","year":"2022","journal-title":"Cancer Lett"},{"issue":"7","key":"zoi251238r8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality.","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"zoi251238r9","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association.","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"zoi251238r10","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1161\/CIRCULATIONAHA.114.015124","article-title":"Association of race with mortality and cardiovascular events in a large cohort of US veterans.","volume":"132","author":"Kovesdy","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"zoi251238r11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1525-1497.2002.20335.x","article-title":"Black-white differences in severity of coronary artery disease among individuals with acute coronary syndromes.","volume":"17","author":"Whittle","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi251238r12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s11914-023-00838-y","article-title":"Racial\/ethnic differences in bone mineral density for osteoporosis.","volume":"21","author":"Wu","year":"2023","journal-title":"Curr Osteoporos Rep"},{"key":"zoi251238r14","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score\u2013based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi251238r16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching.","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"4","key":"zoi251238r17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41391-021-00369-6","article-title":"Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control.","volume":"24","author":"van Son","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"zoi251238r18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.","volume":"8","author":"Saylor","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"zoi251238r19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/0970-1591.52907","article-title":"Adverse effects of androgen deprivation therapy in prostate cancer: current management issues.","volume":"25","author":"Bagrodia","year":"2009","journal-title":"Indian J Urol"},{"issue":"9","key":"zoi251238r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"zoi251238r21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"zoi251238r23","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"zoi251238r24","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1359\/jbmr.2003.18.12.2238","article-title":"Racial differences in bone mineral density in older men.","volume":"18","author":"George","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"11","key":"zoi251238r25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer.","volume":"6","author":"Rachner","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"zoi251238r26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"issue":"6","key":"zoi251238r27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","article-title":"Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.","volume":"104","author":"Wadhwa","year":"2009","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"zoi251238r28","first-page":"S35","article-title":"Hormonal therapy for prostate cancer.","volume":"8","author":"Brawer","year":"2006","journal-title":"Rev Urol"},{"issue":"3","key":"zoi251238r29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.juro.2011.10.136","article-title":"Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.","volume":"187","author":"Morgans","year":"2012","journal-title":"J Urol"},{"key":"zoi251238r1","unstructured":"Rodrigues? M, Wong? WW, Boorjian? SA. Clinically localized prostate cancer: AUA\/ASTRO guideline 2022. Accessed October 16, 2025. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/clinically-localized-prostate-cancer-aua\/astro-guideline-2022"},{"key":"zoi251238r13","unstructured":"Yang? D, Dalton? JE. A unified approach to measuring the effect size between two groups using SAS. SAS Global Forum. 2012. Accessed October 15, 2025. https:\/\/support.sas.com\/resources\/papers\/proceedings12\/335-2012.pdf"},{"key":"zoi251238r15","unstructured":"Caswell? J. A SAS macro for calculating standardized differences of means and proportions. 2018. Accessed October 16, 2025. https:\/\/www.academia.edu\/37917760\/A_SAS_Macro_for_Calculating_Standardized_Differences_of_Means_and_Proportions"},{"key":"zoi251238r22","unstructured":"US Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. October 20, 2010. Accessed October 16, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-update-ongoing-safety-review-gnrh-agonists-and-notification"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2841636\/friedrich_2025_oi_251238_1762977905.36703.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:00:24Z","timestamp":1763568024000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2841636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.45705","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}